Back to Search Results

The potential of methylxanthine-based therapies in pediatric respiratory tract diseases.

Official College of Pharmacists of Gipuzkoa, 20006 San Sebastian, Spain. Electronic address: ainhoaonatibia@redfarma.org. Neuroscience Department, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain. Electronic address: martinezpinillaeva@gmail.com. Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain; CIBERNED, Centro de Investigación en Red, Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, 28049 Madrid, Spain; Institute of Biomedicine of the University of Barcelona, IBUB, 08028, Barcelona, Spain. Electronic address: rfranco123@gmail.com.

Respiratory medicine. 2016;:1-9
Full text from:

Other resources

Abstract

Caffeine, theophylline and theobromine are the most known methylxanthines as they are present in coffee, tea and/or chocolate. In the last decades, a huge experimental effort has been devoted to get insight into the variety of actions that these compounds exert in humans. From such knowledge it is known that methylxanthines have a great potential in prevention, therapy and/or management of a variety of diseases. The benefits of methylxanthine-based therapies in the apnea of prematurity and their translational potential in pediatric affections of the respiratory tract are here presented.

Methodological quality

Publication Type : Review

Metadata